Chinese Expert Consensus on Immunotherapy for Renal Cell Carcinoma
Chinese Kidney Cancer Consortium Chinese Urological Association
Ma Xin
Zhang Xu
Abstract：Immunotherapy combined with targeted therapy has become the first-line standard treatment for ad-vanced renal cell carcinoma(RCC)and has made groundbreaking progress in the perioperative setting.Furthermore,immunotherapy-centered combination strategies are actively being explored in various clinical scenarios for RCC.However,there is currently a lack of guidelines and consensus to direct clinical practice.Based on the latest clinical re-search data on immunotherapy for RCC,the Chinese Kidney Cancer Consortium Chinese Urological Association or-ganized an in-depth discussion among expert panel members to develop this consensus.This document provides de-tailed recommendations for immunotherapy in locally advanced RCC and metastatic or unresectable RCC.It also dis-cuss the relationship between surgical treatment and immunotherapy,as well as the management of adverse events as-sociated with immunotherapy combined with targeted therapy,aiming to offer guidance for clinical practice.
Keywords：kidney cancerimmunotherapycombination of immunotherapy and target therapyconsensus
Publication Date：2025-04-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：11( 73-83 )